By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
As Western heat wave ends, scientists try to make sense of its length and intensity - 2Dominating the Remote Work Way of life: Individual Systems
- 3Energy agency chief warns of 'black April' for oil supplies
- 4The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 5Popular Film Areas: A Worldwide Manual for Film Enchantment
- Israel and Lebanon's Hezbollah continue to trade attacks
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey
- Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- Excelling at Cash The board: A Manual for Monetary Essentials
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- Creative Do-It-Yourself Ventures for Each Expertise Level
